The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A five-arm, open-label, phase I/lb study to assess safety and tolerability of the oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with chemotherapy or erlotinib in patients with advanced solid tumors.
Carlos Becerra
Honoraria - Lilly
Research Funding - Lilly
Jeffrey R. Infante
No relevant relationships to disclose
Lawrence E. Garbo
No relevant relationships to disclose
Michael S. Gordon
Consultant or Advisory Role - GlaxoSmithKline (U)
Honoraria - GlaxoSmithKline
Research Funding - GlaxoSmithKline
David A. Smith
No relevant relationships to disclose
Fadi S. Braiteh
Consultant or Advisory Role - Amgen; Caris MPI; Celgene; Eisai; Genomic Health; Millennium; Myriad Genetics; Novartis; Pfizer; Spectrum Pharmaceuticals
Research Funding - Genentech; GlaxoSmithKline; Lilly; Merrimack; Mersana; Millennium; Novartis; Pfizer
David R. Gandara
Consultant or Advisory Role - Amgen; AstraZeneca; Bioarray Therapeutics ; Biodesix; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech; ImClone Systems; Merck; Novartis; Response Genetics; Sanofi
Research Funding - Bristol-Myers Squibb; Genentech; ImClone Systems; Lilly; Merck; Novartis
Robert M. Jotte
No relevant relationships to disclose
Karen L. Reckamp
Consultant or Advisory Role - Amgen; Genentech; Tragara Pharmaceuticals
Honoraria - Genentech; Lilly
Research Funding - Agennix; Amgen; Astellas Pharma; GlaxoSmithKline; Pfizer
Filip Janku
No relevant relationships to disclose
Howard A. Burris
No relevant relationships to disclose
Kevin M. Bellew
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Research Funding - GlaxoSmithKline
Olivia S. Gardner
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Li Liu
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Donna S Cox
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Vijay Gopal Reddy Peddareddigari
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
George R. Blumenschein
Research Funding - GlaxoSmithKline